Saturday 17 October 2026
Export MPLT’s income statement to Excel — free account
MapLight Therapeutics, Inc.
MPLT Healthcare Biotechnology
In the quarter to June 2026, EPS grew 96.6% and free cash flow fell 31.9%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.70
0.32
−3.99%
Follow MPLT
| Dec '25 | Dec '24 | |
|---|---|---|
Current Ratio |
20.01 | 7.20 |
Net Debt/EBITDA |
1.79 | 1.30 |
Debt/Assets |
0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 |
Asset Turnover |
0.00 | — |
Operating CF/Net income |
0.86 | 1.02 |
Capex/Depreciation |
0.31 | 0.74 |
| (121.74%) | 0.00% | |
| (52.29%) | 0.00% | |
ROIC |
(68.95%) | 0.00% |
Return on Tangible Assets |
(52.06%) | (77.67%) |
Research and Development Expense of Revenue |
0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% |
Free Cash Flow per Share |
(15.97) | (108.10) |
Cash per Share |
35.15 | 147.78 |
Shareholders Equity per Share |
52.80 | (263.01) |
Interest Debt per Share |
0.00 | 0.00 |
Book value per Share |
52.80 | (263.01) |
Free Cash Flow |
(138.61) | (79.58) |
Working Capital |
308.44 | 98.68 |
Capital Expenditures |
(0.47) | (0.77) |
Net Current Asset Value |
303.53 | 92.88 |
| Other line items | ||
Quick Ratio |
18.80 | 6.83 |
Depreciation/Fixed assets |
(1.39) | (0.86) |
Cash ROIC |
(18.16%) | 93.81% |
Accounts Payable Turnover |
0.00 | — |
Average Days of Payables |
0.00 | 0.00 |
Revenue per Share |
0.00 | 0.00 |
Operating CF per Share |
(15.91) | (107.06) |
Capex per Share |
(0.05) | (1.05) |
Average Payables |
2.60 | — |
Average Assets |
308.21 | — |
Average Common Equity |
132.37 | — |
Capex to Sales |
0.00 | 0.00 |
Columns are period end dates